Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for  GCH1  mutations | Zendy

Furukawa Yoshiaki | Zendy; Filiano James J. | Zendy; Kish Stephen J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations

Author(s) -

Furukawa Yoshiaki,

Filiano James J.,

Kish Stephen J.

Publication year - 2004

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.20194

Subject(s) - amantadine , levodopa , dyskinesia , dystonia , parkinsonism , medicine , compound heterozygosity , neurological disorder , movement disorders , paroxysmal dyskinesia , pharmacology , psychology , mutation , central nervous system disease , neuroscience , parkinson's disease , genetics , biology , gene , disease

Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research